Patents by Inventor Yasuo Shinoda

Yasuo Shinoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8101207
    Abstract: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of ±40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2?) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: January 24, 2012
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroshi Miura, Makoto Kanebako, Masayuki Kanishi, Yasuo Shinoda, Toshio Inagi, Hirofumi Takeuchi
  • Patent number: 7553865
    Abstract: An object of the present invention is to provide an indomethacin external preparation that has an excellent use feeling and excellent absorbability and causes no phase separation into an oil layer and an aqueous layer, thus exhibiting satisfactory stability of preparation with time. Provided is an indomethacin external preparation containing: 0.1 to 3 wt % of indomethacin; 25 to 50 wt % of alcohol; 0.01 to 5 wt % of gelling agent; 5 to 30 wt % of oil component; 20 to 50 wt % of water; and 0.01 to 10 wt % of one or more components selected from the group consisting of glyceryl monostearate, sorbitan monostearate, stearyl alcohol, and polyethylene glycol monostearate.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: June 30, 2009
    Assignee: Kowa Company, Ltd.
    Inventors: Hiroyuki Shirai, Tatsuya Nakai, Masami Serizawa, Yasuo Shinoda, Toshio Inagi
  • Publication number: 20070128273
    Abstract: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of ±40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2?) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.
    Type: Application
    Filed: April 28, 2004
    Publication date: June 7, 2007
    Applicant: Kowa Co., Ltd.
    Inventors: Hiroshi Miura, Makoto Kanebako, Masayuki Kanishi, Yasuo Shinoda, Toshio Inagi, Hirofumi Takeuchi
  • Publication number: 20050239868
    Abstract: An object of the present invention is to provide an indomethacin external preparation that has an excellent use feeling and excellent absorbability and causes no phase separation into an oil layer and an aqueous layer, thus exhibiting satisfactory stability of preparation with time. Provided is an indomethacin external preparation containing: 0.1 to 3 wt % of indomethacin; 25 to 50 wt % of alcohol; 0.01 to 5 wt % of gelling agent; 5 to 30 wt % of oil component; 20 to 50 wt % of water; and 0.01 to 10 wt % of one or more components selected from the group consisting of glyceryl monostearate, sorbitan monostearate, stearyl alcohol, and polyethylene glycol monostearate.
    Type: Application
    Filed: July 22, 2003
    Publication date: October 27, 2005
    Inventors: Hiroyuki Shirai, Tatsuya Nakai, Masami Serizawa, Yasuo Shinoda, Toshio Inagi
  • Patent number: 6753330
    Abstract: The invention provides a solid dispersion composition containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, hydroxypropylmethyl cellulose, and polyoxyethylene polyoxypropylene glycol. The solid dispersion composition of the present invention exhibits the excellent dissolvability of 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one in water, and enables this compound to be constant sequentially and thereby improve absorbability in blood.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: June 22, 2004
    Assignee: Kowa Co., Ltd.
    Inventors: Niichiro Takano, Hiroyuki Kawashima, Yasuo Shinoda, Toshio Inagi
  • Publication number: 20040067909
    Abstract: An object of present invention is to provide an eye drop which causes no uncomfortable irritation upon instillation and shows favorable long-term storage stability of CPB-I. The eye drop which comprises CPB-I and a polyhydric alcohol, preferably the polyhydric alcohol having a carbonyl value of 5 &mgr;mol/g or lower, can be provided.
    Type: Application
    Filed: August 25, 2003
    Publication date: April 8, 2004
    Inventors: Haruhiko Naruse, Misato Sano, Yasuo Shinoda, Toshio Inagi
  • Publication number: 20040018235
    Abstract: The present invention is drawn to a pharmaceutical composition characterized by containing a composition (A) which contains pitavastatin, a salt thereof, or an ester thereof and which initiates release thereof at least in the stomach, and an enteric composition (B) which contains pitavastatin, a salt thereof, or an ester thereof. By use of the controlled release pharmaceutical composition of the present invention, the blood level of pitavastatin can be maintained at an appropriate level immediately after administration over a long period of time. Thus, highly safety and effective treatment of hypercholesterolemia can be performed.
    Type: Application
    Filed: June 16, 2003
    Publication date: January 29, 2004
    Applicants: KOWA CO., LTD, Nissan Chemical Industries Limited
    Inventors: Yoshio Tanizawa, Tatsuharu Shimokawa, Hirotada Ogawa, Mayumi Watanabe, Chihiro Ohashi, Hiroyuki Kawashima, Yasuo Shinoda, Toshio Inagi
  • Publication number: 20040019122
    Abstract: The invention provides a solid dispersion composition containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, hydroxypropylmethyl cellulose, and polyoxyethylene polyoxypropylene glycol. The solid dispersion composition of the present invention exhibits the excellent dissolvability of 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one in water, and enables this compound to be constant sequentially and thereby improve absorbability in blood.
    Type: Application
    Filed: April 16, 2003
    Publication date: January 29, 2004
    Applicant: KOWA CO., LTD.
    Inventors: Niichiro Takano, Hiroyuki Kawashima, Yasuo Shinoda, Toshio Inagi
  • Publication number: 20030187070
    Abstract: A fill liquid composition for capsules is produced by mixing ibuprofen, polyethylene glycol, water and terpenoid selected from menthol, limonene, borneol, dl-camphor, peppermint oil and so forth, and optionally one or more agents selected from antipyretic analgesic, anti-histamine, antitussive, expectorant, sympathetic nerve stimulant, central stimulant, hypnotic sedative and antiphlogistic, and solubilizing agent, viscous agent, pH adjuster, coloring agent, and the like, in order to exhibit the effects that the prevention of bitterness of ibuprofen and the quick-activeness of ibuprofen are consistently achieved.
    Type: Application
    Filed: February 13, 2003
    Publication date: October 2, 2003
    Inventors: Soichiro Kato, Katsuyuki Tsumori, Yasuo Shinoda, Toshio Inagi
  • Publication number: 20030064959
    Abstract: A gel preparation comprising urea, an acrylic acid polymer and a xanthan gum.
    Type: Application
    Filed: October 23, 2002
    Publication date: April 3, 2003
    Inventors: Yoshitoshi Sawada, Shinya Yamamoto, Saibi Suehiro, Toshio Inagi, Yasuo Shinoda
  • Patent number: 6465477
    Abstract: Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4′-4″-fluorophenyl-2′-cyclopropyl-quinolin-3′-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has pH of from 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: October 15, 2002
    Assignees: Kowa Company, Ltd., Nissan Chemical Industries, Ltd.
    Inventors: Toyojiro Muramatsu, Katsumi Mashita, Yasuo Shinoda, Hironori Sassa, Hiroyuki Kawashima, Yoshio Tanizawa, Hideatsu Takeuchi